scholarly journals Injectable in situ forming hydrogels based on natural and synthetic polymers for potential application in cartilage repair

RSC Advances ◽  
2015 ◽  
Vol 5 (25) ◽  
pp. 19715-19723 ◽  
Author(s):  
Calogero Fiorica ◽  
Fabio Salvatore Palumbo ◽  
Giovanna Pitarresi ◽  
Alessandro Gulino ◽  
Stefano Agnello ◽  
...  

Injectable hydrogels based on hyaluronic acid, elastin and a biocompatible polyaspartamide are optimal scaffolds of viable chondrocytes for potential cartilage repair.

2017 ◽  
Vol 74 (10) ◽  
pp. 4069-4085 ◽  
Author(s):  
Takeshi Sato ◽  
Takao Aoyagi ◽  
Mitsuhiro Ebara ◽  
Rachel Auzély-Velty

2015 ◽  
Vol 122 ◽  
pp. 408-416 ◽  
Author(s):  
Fabio S. Palumbo ◽  
Calogero Fiorica ◽  
Mauro Di Stefano ◽  
Giovanna Pitarresi ◽  
Alessandro Gulino ◽  
...  

Soft Matter ◽  
2012 ◽  
Vol 8 (18) ◽  
pp. 4918 ◽  
Author(s):  
Fabio Salvatore Palumbo ◽  
Giovanna Pitarresi ◽  
Calogero Fiorica ◽  
Pietro Matricardi ◽  
Antonella Albanese ◽  
...  

2020 ◽  
Author(s):  
Isabel Pereira ◽  
José Eduardo Pereira ◽  
Luís Maltez ◽  
Alexandra Rodrigues ◽  
Catarina Rodrigues ◽  
...  

Abstract The development of injectable bone substitutes (IBS) have obtained great importance in the bone regeneration field, as a strategy to reach hardly accessible defects using minimally invasive techniques and able to fit to irregular topographies. In this scenario, the association of injectable hydrogels and bone graft granules is emerging as a well-established trend. Particularly, in situ forming hydrogels have arisen as a new IBS generation. An in situ forming and injectable dextrin-based hydrogel (HG) was developed, aiming to act as a carrier of granular bone substitutes and bioactive agents. In this work, the HG was associated to a granular bone substitute (Bonelike®) and implanted in goat critical-sized calvarial defects (14 mm) for 3, 6 and 12 weeks. The results showed that HG improved the handling properties of the Bonelike® granules and did not affect its osteoconductive features, neither impairing the bone regeneration process. Human multipotent mesenchymal stromal cells from the umbilical cord, extracellular matrix hydrolysates and the pro-angiogenic peptide LLKKK18 were also combined with the IBS. These bioactive agents did not enhance the new bone formation significantly under the conditions tested, according to micro-computed tomography and histological analysis.


Polymers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1138
Author(s):  
Lixuan Wang ◽  
Shiyan Dong ◽  
Yutong Liu ◽  
Yifan Ma ◽  
Jingjing Zhang ◽  
...  

Injectable hydrogels have been widely applied in the field of regenerative medicine. However, current techniques for injectable hydrogels are facing a challenge when trying to generate a biomimetic, porous architecture that is well-acknowledged to facilitate cell behaviors. In this study, an injectable, interconnected, porous hyaluronic acid (HA) hydrogel based on an in-situ bubble self-generation and entrapment process was developed. Through an amide reaction between HA and cystamine dihydrochloride activated by EDC/NHS, CO2 bubbles were generated and were subsequently entrapped inside the substrate due to a rapid gelation-induced retention effect. HA hydrogels with different molecular weights and concentrations were prepared and the effects of the hydrogel precursor solution’s concentration and viscosity on the properties of hydrogels were investigated. The results showed that HA10-10 (10 wt.%, MW 100,000 Da) and HA20-2.5 (2.5 wt.%, MW 200,000 Da) exhibited desirable gelation and obvious porous structure. Moreover, HA10-10 represented a high elastic modulus (32 kPa). According to the further in vitro and in vivo studies, all the hydrogels prepared in this study show favorable biocompatibility for desirable cell behaviors and mild host response. Overall, such an in-situ hydrogel with a self-forming bubble and entrapment strategy is believed to provide a robust and versatile platform to engineer injectable hydrogels for a variety of applications in tissue engineering, regenerative medicine, and personalized therapeutics.


2019 ◽  
Vol 108 (3) ◽  
pp. 790-797
Author(s):  
Jing‐Wan Luo ◽  
Chang Liu ◽  
Jing‐Heng Wu ◽  
Dan‐Hui Zhao ◽  
Long‐Xiang Lin ◽  
...  

2020 ◽  
Vol 12 (2) ◽  
pp. 2023-2038 ◽  
Author(s):  
Jun Li ◽  
Fan Yu ◽  
Gong Chen ◽  
Jia Liu ◽  
Xiao-Long Li ◽  
...  

2015 ◽  
Vol 137 (4) ◽  
pp. 1618-1622 ◽  
Author(s):  
Vinh X. Truong ◽  
Matthew P. Ablett ◽  
Stephen M. Richardson ◽  
Judith A. Hoyland ◽  
Andrew P. Dove

Sign in / Sign up

Export Citation Format

Share Document